Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03427814




Registration number
NCT03427814
Ethics application status
Date submitted
5/02/2018
Date registered
9/02/2018
Date last updated
21/09/2023

Titles & IDs
Public title
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
Scientific title
A Phase 2, Double-blind, Randomized Study of BGB-290 Versus Placebo as Maintenance Therapy in Patients With Inoperable Locally Advanced or Metastatic Gastric Cancer That Responded to Platinum-based First-line Chemotherapy
Secondary ID [1] 0 0
2017-003493-13
Secondary ID [2] 0 0
BGB-290-303
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced or Inoperable Gastric Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Stomach

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pamiparib
Treatment: Drugs - Placebo

Experimental: Pamiparib - Participants received pamiparib orally.

Placebo Comparator: Placebo - Participants received placebo orally.


Treatment: Drugs: Pamiparib
60 mg orally twice daily

Treatment: Drugs: Placebo
60 mg orally twice daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) by Investigator Assessment
Timepoint [1] 0 0
Approximately 23 months
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Approximately 23 months
Secondary outcome [2] 0 0
Time To Second Subsequent Treatment (TSST)
Timepoint [2] 0 0
Approximately 23 months
Secondary outcome [3] 0 0
Objective Response Rate (ORR)
Timepoint [3] 0 0
Approximately 23 months
Secondary outcome [4] 0 0
Duration of Response (DOR)
Timepoint [4] 0 0
Approximately 23 months
Secondary outcome [5] 0 0
Time To Response
Timepoint [5] 0 0
Approximately 23 months
Secondary outcome [6] 0 0
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Timepoint [6] 0 0
From start of study treatment until 30 days after the last study drug intake or initiation of new anticancer therapy, whichever occurs first (up to approximately 4 years and 5.5 months)

Eligibility
Key inclusion criteria
Key

1. Age = 18 years.

2. Signed informed consent.

3. Histologically confirmed inoperable locally advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction.

4. Received platinum based first line chemotherapy for = 28 weeks.

5. Confirmed partial response (PR) maintained for = 4 weeks or complete response (CR).

6. Able to be randomized to study = 8 weeks after last platinum dose.

7. Eastern Cooperative Oncology Group (ECOG) performance status = 1.

8. Adequate hematologic, renal and hepatic function.

9. Must be able to provide archival tumor tissue for central biomarker assessment.

10. Females of childbearing potential and non-sterile males must agree to use highly
effective methods of birth control throughout the course of study and at least up to 6
months after last dosing.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Unresolved acute effects of prior therapy = Grade 2.

2. Prior treatment with PARP inhibitor.

3. Chemotherapy, biologic therapy, immunotherapy or other anticancer therapy = 14 days
prior to randomization.

4. Major surgery or significant injury = 2 weeks prior to start of study treatment.

5. Diagnosis of myelodysplastic syndrome (MDS)

6. Other diagnoses of significant malignancy

7. Leptomeningeal disease or brain metastasis

8. Inability to swallow capsules or disease affecting gastrointestinal function.

9. Active infections requiring systemic treatment.

10. Clinically significant cardiovascular disease

11. Pregnant or nursing females.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/07/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
3/01/2023
Sample size
Target
Accrual to date
Final
136
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Central Coast Local Health District - Gosford
Recruitment hospital [2] 0 0
The Townsville Hospital and Health Service - Douglas
Recruitment hospital [3] 0 0
Monash Health - Clayton
Recruitment hospital [4] 0 0
Northern Hospital - Epping
Recruitment hospital [5] 0 0
Ballarat Oncology and Haematology Services - Wendouree
Recruitment postcode(s) [1] 0 0
2250 - Gosford
Recruitment postcode(s) [2] 0 0
4814 - Douglas
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3076 - Epping
Recruitment postcode(s) [5] 0 0
3355 - Wendouree
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Kansas
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Oklahoma
Country [8] 0 0
United States of America
State/province [8] 0 0
Oregon
Country [9] 0 0
United States of America
State/province [9] 0 0
Tennessee
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
Belgium
State/province [11] 0 0
Antwerpen
Country [12] 0 0
Belgium
State/province [12] 0 0
Oost-Vlaanderen
Country [13] 0 0
Belgium
State/province [13] 0 0
Vlaams Brabant
Country [14] 0 0
Belgium
State/province [14] 0 0
West-Vlaanderen
Country [15] 0 0
Belgium
State/province [15] 0 0
Liège
Country [16] 0 0
China
State/province [16] 0 0
Anhui
Country [17] 0 0
China
State/province [17] 0 0
Beijing
Country [18] 0 0
China
State/province [18] 0 0
Fujian
Country [19] 0 0
China
State/province [19] 0 0
Guangdong
Country [20] 0 0
China
State/province [20] 0 0
Heilongjiang
Country [21] 0 0
China
State/province [21] 0 0
Henan
Country [22] 0 0
China
State/province [22] 0 0
Hunan
Country [23] 0 0
China
State/province [23] 0 0
Jiangsu
Country [24] 0 0
China
State/province [24] 0 0
Liaoning
Country [25] 0 0
China
State/province [25] 0 0
Shandong
Country [26] 0 0
China
State/province [26] 0 0
Shanghai
Country [27] 0 0
China
State/province [27] 0 0
Tianjin
Country [28] 0 0
China
State/province [28] 0 0
Zhejiang
Country [29] 0 0
China
State/province [29] 0 0
Guangzhou
Country [30] 0 0
China
State/province [30] 0 0
Nanjing
Country [31] 0 0
Czechia
State/province [31] 0 0
Olomouc
Country [32] 0 0
Czechia
State/province [32] 0 0
Praha
Country [33] 0 0
France
State/province [33] 0 0
Alpes Maritimes
Country [34] 0 0
France
State/province [34] 0 0
Bretagne
Country [35] 0 0
France
State/province [35] 0 0
Franche-Comté
Country [36] 0 0
France
State/province [36] 0 0
Haute-Garonne
Country [37] 0 0
France
State/province [37] 0 0
Ille-et-Vilaine
Country [38] 0 0
France
State/province [38] 0 0
Languedoc-Roussillon
Country [39] 0 0
France
State/province [39] 0 0
Rhône
Country [40] 0 0
France
State/province [40] 0 0
Vienne
Country [41] 0 0
France
State/province [41] 0 0
Angers Cedex 02
Country [42] 0 0
France
State/province [42] 0 0
Angers Cedex 2
Country [43] 0 0
France
State/province [43] 0 0
Île-de-France
Country [44] 0 0
Georgia
State/province [44] 0 0
Tamar
Country [45] 0 0
Georgia
State/province [45] 0 0
Tbilisi
Country [46] 0 0
Hong Kong
State/province [46] 0 0
Hong Kong
Country [47] 0 0
Hungary
State/province [47] 0 0
Jász-Nagykun-Szolnok
Country [48] 0 0
Hungary
State/province [48] 0 0
Szabolcs-Szatmár-Bereg
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Hungary
State/province [50] 0 0
Debrecen
Country [51] 0 0
Hungary
State/province [51] 0 0
Pécs
Country [52] 0 0
Japan
State/province [52] 0 0
Aiti [Aichi]
Country [53] 0 0
Japan
State/province [53] 0 0
Histao
Country [54] 0 0
Japan
State/province [54] 0 0
Hukuoka [Fukuoka]
Country [55] 0 0
Japan
State/province [55] 0 0
Kanagawa
Country [56] 0 0
Japan
State/province [56] 0 0
Osaka
Country [57] 0 0
Japan
State/province [57] 0 0
Chuo Ku
Country [58] 0 0
Japan
State/province [58] 0 0
Fukuoka
Country [59] 0 0
Japan
State/province [59] 0 0
Hirakata
Country [60] 0 0
Japan
State/province [60] 0 0
Hyogo
Country [61] 0 0
Japan
State/province [61] 0 0
Kumamoto
Country [62] 0 0
Japan
State/province [62] 0 0
Osaka-shi
Country [63] 0 0
Japan
State/province [63] 0 0
Saitama
Country [64] 0 0
Japan
State/province [64] 0 0
Sapporo
Country [65] 0 0
Japan
State/province [65] 0 0
Takatsuki
Country [66] 0 0
Japan
State/province [66] 0 0
Utsunomiya
Country [67] 0 0
Poland
State/province [67] 0 0
Lódzkie
Country [68] 0 0
Poland
State/province [68] 0 0
Mazowieckie
Country [69] 0 0
Poland
State/province [69] 0 0
Podkarpackie
Country [70] 0 0
Poland
State/province [70] 0 0
Gdynia
Country [71] 0 0
Poland
State/province [71] 0 0
Lublin
Country [72] 0 0
Poland
State/province [72] 0 0
Poznan
Country [73] 0 0
Romania
State/province [73] 0 0
Bucuresti
Country [74] 0 0
Romania
State/province [74] 0 0
Cluj-Napoca
Country [75] 0 0
Romania
State/province [75] 0 0
Constanta
Country [76] 0 0
Romania
State/province [76] 0 0
Craiova
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Krasnodarskiy Kray
Country [78] 0 0
Russian Federation
State/province [78] 0 0
Krasnodar
Country [79] 0 0
Russian Federation
State/province [79] 0 0
Moscow
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Perm
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Saint Petersburg
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Samara
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Volgograd
Country [84] 0 0
Singapore
State/province [84] 0 0
Central Singapore
Country [85] 0 0
Singapore
State/province [85] 0 0
Singapore
Country [86] 0 0
Spain
State/province [86] 0 0
Barcelona
Country [87] 0 0
Spain
State/province [87] 0 0
Madrid
Country [88] 0 0
Spain
State/province [88] 0 0
Navarra
Country [89] 0 0
Spain
State/province [89] 0 0
Alcorcón
Country [90] 0 0
Spain
State/province [90] 0 0
Sevilla
Country [91] 0 0
Spain
State/province [91] 0 0
Valencia
Country [92] 0 0
Spain
State/province [92] 0 0
Zaragoza
Country [93] 0 0
Taiwan
State/province [93] 0 0
Tainan
Country [94] 0 0
Taiwan
State/province [94] 0 0
Taipei
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Greater London
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Nottinghamshire
Country [97] 0 0
United Kingdom
State/province [97] 0 0
London
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Northwood
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Peterborough

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
BeiGene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study enrolled participants with previously-treated advanced or inoperable gastric
cancer who have responded to first line platinum therapy into two treatment arms. In Arm A
participants received BGB-290; in Arm B participants received placebo. The purpose of this
study is to show that BGB-290 (pamiparib) (versus placebo) will improve progression-free
survival (PFS) in participants with advanced or inoperable gastric cancer.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03427814
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
BeiGene
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03427814